While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Gilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Hulu's The Handmaid's Tale has finally concluded its sixth season after eight years of its premiere. The show, based on ...

The series had introduced Elisabeth Moss as June, a mother and wife who was captured by the totalitarian fascist regime the ...

"The Handmaid's Tale" comes to an end after six seasons on Hulu. One of the stars, O-T Fagbenle, talks about his character ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...